Physician profile
Sofia C Luna
NPI 1518177138
$6,291.98
in general payments reported to CMS, 2019-2025
47 companies · $1,121 in 2025
The $1,121 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $597 · 2022: $625 · 2023: $1,593 · 2024: $2,356 · 2025: $1,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,069.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,719.79 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $423.10 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.16 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $326.25 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $277.78 | 2022-2025 | Otezla, Repatha, Evenity |
| Almatica Pharma LLC | $256.97 | 2022-2024 | Loreev Xr, Gralise, Sertraline Hcl |
| Glaxosmithkline, LLC. | $254.02 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $202.48 | 2023-2025 | |
| Abbott Laboratories | $196.31 | 2022-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $191.16 | 2021-2024 | Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $183.78 | 2022-2025 | Caplyta |
| Sumitomo Pharma America, INC. | $182.57 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.16 | 2022-2025 | Xifaxan |
| Dexcom, INC. | $149.82 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $99.16 | 2021-2023 | Belsomra, Steglatro |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofia Luna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.